

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

**APPLICATION NUMBER: 20-986/SE3-003**

**CORRESPONDENCE**

Redacted 3

pages of trade

secret and/or

confidential

commercial

information

**Rhee, H Julie**

**From:** LOKO@nnpi.com  
**At:** Friday, December 21, 2001 6:22 PM  
**To:** RHEEJ@cder.fda.gov; ELTA@nnpi.com; LOKO@nnpi.com  
**Subject:** RE: NovoLog Supplement letter

Dear Julie:

We acknowledge that we received the approval letter NDA 20-986/S-003.

Regards, Lois

-----Original Message-----

**From:** Rhee, H Julie [mailto:RHEEJ@cder.fda.gov]  
**Sent:** Friday, December 21, 2001 6:11 PM  
**To:** elta@nnpi.com; loko@nnpi.com  
**Subject:** NovoLog Supplement letter

<< File: Supp 003 AP letter to Novo.pdf >> Dear Elizabeth and Lois,

Here's the approval letter for supplement 003.

Please let me know when you receive the letter. I just realized that I used a wrong NDA number on PPI's header. Please disregard it.

Thank you,

ie

<<Supp 003 AP letter to Novo.pdf>>

**APPEARS THIS WAY  
ON ORIGINAL**